ZA961349B - Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications - Google Patents

Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications

Info

Publication number
ZA961349B
ZA961349B ZA961349A ZA961349A ZA961349B ZA 961349 B ZA961349 B ZA 961349B ZA 961349 A ZA961349 A ZA 961349A ZA 961349 A ZA961349 A ZA 961349A ZA 961349 B ZA961349 B ZA 961349B
Authority
ZA
South Africa
Prior art keywords
sequences
expression
amplifying
compositions
vectors
Prior art date
Application number
ZA961349A
Other languages
English (en)
Inventor
Denise Paulin
Zehn Lin Li
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of ZA961349B publication Critical patent/ZA961349B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA961349A 1995-02-20 1996-02-20 Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications ZA961349B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9501937A FR2730735B1 (fr) 1995-02-20 1995-02-20 Sequences amplificatrices, vecteurs portant ces sequences et leurs utilisations dans des compositions pour l'expression de sequences nucleotidiques dans des cellules transfectees, applications therapeutiques et vaccinales

Publications (1)

Publication Number Publication Date
ZA961349B true ZA961349B (en) 1996-09-05

Family

ID=9476320

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961349A ZA961349B (en) 1995-02-20 1996-02-20 Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications

Country Status (15)

Country Link
US (2) US5914395A (xx)
EP (1) EP0811071B1 (xx)
JP (1) JPH11500905A (xx)
AT (1) ATE212060T1 (xx)
AU (1) AU710697B2 (xx)
CA (1) CA2211435A1 (xx)
DE (1) DE69618574T2 (xx)
DK (1) DK0811071T3 (xx)
ES (1) ES2168459T3 (xx)
FR (1) FR2730735B1 (xx)
IL (1) IL117194A0 (xx)
MX (1) MX9706290A (xx)
PT (1) PT811071E (xx)
WO (1) WO1996026284A1 (xx)
ZA (1) ZA961349B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2246664A1 (en) * 1998-10-02 2000-04-02 Universite Paris 7 Vascular specific regulatory elements contained in the desmin 5' flanking region
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
EP2691530B1 (en) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
AU2015208247B2 (en) * 2014-01-21 2021-05-27 Universiteit Gent Muscle-specific nucleic acid regulatory elements and methods and use thereof
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US5503980A (en) * 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization

Also Published As

Publication number Publication date
DE69618574T2 (de) 2002-08-14
CA2211435A1 (fr) 1996-08-29
AU4835696A (en) 1996-09-11
US5914395A (en) 1999-06-22
ATE212060T1 (de) 2002-02-15
IL117194A0 (en) 1996-06-18
AU710697B2 (en) 1999-09-30
US6201115B1 (en) 2001-03-13
DE69618574D1 (de) 2002-02-21
JPH11500905A (ja) 1999-01-26
PT811071E (pt) 2002-07-31
EP0811071B1 (fr) 2002-01-16
MX9706290A (es) 1998-02-28
WO1996026284A1 (fr) 1996-08-29
FR2730735A1 (fr) 1996-08-23
DK0811071T3 (da) 2002-04-29
EP0811071A1 (fr) 1997-12-10
ES2168459T3 (es) 2002-06-16
FR2730735B1 (fr) 1997-05-09

Similar Documents

Publication Publication Date Title
ZA961349B (en) Amplifying sequences vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells therapeutic and vaccine applications
EP1209237A3 (en) Synthetic DNA sequence having enhanced insecticidal activity in maize
HUP0204199A2 (hu) Transzport vektorok
AU8067698A (en) Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus
DE69429631D1 (en) Conotoxinpeptide
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
AU2003264419A1 (en) Kdr peptides and vaccines containing the same
IL133544A0 (en) Lag-3 splice variants, their preparation and use
WO2001036623A3 (en) Ecdysone-inducible adeno-associated virus expression vectors
WO2003093417A3 (en) Lentiviral vector particles resistant to complement inactivation
CA2327266A1 (en) Pesticidal toxins and nucleotide sequences which encode these toxins
AU6724794A (en) GRB3-3 gene, its variants and their uses
WO1999028439A3 (fr) Erythrovirus et ses applications
FR2685004B1 (xx)
AU5776799A (en) Modified hcv peptide vaccines
WO2000012741A3 (fr) Systeme d'expression inductible
ATE327321T1 (de) Zyklische depsipeptid-synthasen, deren gene und system zur massenproduktion von zyklischen depsipeptiden
GB9416536D0 (en) Orphan receptor
AU782261C (en) Novel glycosyltransferase genes
HUP0004857A2 (hu) T. variabilisból származó D-aminosav oxidáz promótere
ES2161130A1 (es) Dna recombinante derivado del virus de la sharka y vector de expresion de proteinas heterologas basado en dicho dna recombinante.
HUP0104598A1 (hu) Hepatocita-eredetű növekedési faktorból (HGF) és makrofágstimuláló proteinből (MSP) származó rekombináns proteinek
CA2419038A1 (en) Nucleic acid and protein increasing expression levels under salt stress
EP1158052A4 (en) BETA-PRIMEVEROSIDASDE GENE